Cargando…
Generation of Antibody-Drug Conjugate Resistant Models
SIMPLE SUMMARY: Antibody-drug conjugates (ADCs) constitute new and effective therapies in cancer. However, resistance is frequently observed in treated patients after a given period of time. That resistance may be present from the beginning of the treatment (primary or de novo resistance) or raise a...
Autores principales: | Gandullo-Sánchez, Lucía, Ocaña, Alberto, Pandiella, Atanasio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466899/ https://www.ncbi.nlm.nih.gov/pubmed/34572858 http://dx.doi.org/10.3390/cancers13184631 |
Ejemplares similares
-
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020) -
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020) -
HER3 in cancer: from the bench to the bedside
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2022) -
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021) -
Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment
por: Juan, Alberto, et al.
Publicado: (2020)